$716 Million is the total value of Eventide Asset Management's 103 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 6.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDVN | MEDIVATION INC | $27,219,000 | +28.3% | 275,300 | 0.0% | 3.80% | +31.7% | |
AGIO | Sell | AGIOS PHARMACEUTICALS INC | $26,479,000 | +17.8% | 431,600 | -12.0% | 3.70% | +21.0% |
PANW | PALO ALTO NETWORKS INC | $20,169,000 | +17.0% | 205,600 | 0.0% | 2.82% | +20.1% | |
TRW | TRW AUTOMOTIVE HLDGS CORP | $20,088,000 | +13.1% | 198,400 | 0.0% | 2.80% | +16.1% | |
ABBV | Buy | ABBVIE INC | $19,101,000 | +15.6% | 330,700 | +13.0% | 2.67% | +18.7% |
CELG | CELGENE CORP | $18,008,000 | +10.4% | 190,000 | 0.0% | 2.51% | +13.3% | |
MIC | MACQUARIE INFRASTR CO LLCmembership int | $17,022,000 | +6.9% | 255,200 | 0.0% | 2.38% | +9.8% | |
LOW | Buy | LOWES COS INC | $16,172,000 | +39.0% | 305,600 | +26.1% | 2.26% | +42.7% |
RHT | RED HAT INC | $15,026,000 | +1.6% | 267,600 | 0.0% | 2.10% | +4.3% | |
LYB | Buy | LYONDELLBASELL INDUSTRIES N | $14,550,000 | +30.8% | 133,900 | +17.6% | 2.03% | +34.3% |
EOG | EOG RES INC | $14,338,000 | -15.3% | 144,800 | 0.0% | 2.00% | -13.0% | |
MGA | MAGNA INTL INC | $14,208,000 | -11.9% | 149,700 | 0.0% | 1.98% | -9.5% | |
BLUE | Buy | BLUEBIRD BIO INC | $14,198,000 | +378.7% | 395,700 | +414.6% | 1.98% | +391.8% |
LEA | LEAR CORP | $13,903,000 | -3.3% | 160,900 | 0.0% | 1.94% | -0.7% | |
SUNEQ | SUNEDISON INC | $13,765,000 | -16.5% | 729,100 | 0.0% | 1.92% | -14.2% | |
DYAX | DYAX CORP | $13,464,000 | +5.4% | 1,330,400 | 0.0% | 1.88% | +8.2% | |
MEOH | METHANEX CORP | $13,447,000 | +8.1% | 201,300 | 0.0% | 1.88% | +11.0% | |
WBC | WABCO HLDGS INC | $13,379,000 | -14.9% | 147,100 | 0.0% | 1.87% | -12.6% | |
LLTC | LINEAR TECHNOLOGY CORP | $12,989,000 | -5.7% | 292,600 | 0.0% | 1.81% | -3.2% | |
CPN | Buy | CALPINE CORP | $12,970,000 | +14.2% | 597,700 | +25.3% | 1.81% | +17.2% |
DATA | Buy | TABLEAU SOFTWARE INCcl a | $12,358,000 | +15.4% | 170,100 | +13.3% | 1.72% | +18.5% |
SYNA | Buy | SYNAPTICS INC | $11,741,000 | -11.9% | 160,400 | +9.0% | 1.64% | -9.6% |
WAB | WABTEC CORP | $11,726,000 | -1.9% | 144,700 | 0.0% | 1.64% | +0.7% | |
CMRX | CHIMERIX INC | $11,562,000 | +25.9% | 418,600 | 0.0% | 1.61% | +29.2% | |
CBI | CHICAGO BRIDGE & IRON CO N V | $11,211,000 | -15.2% | 193,800 | 0.0% | 1.56% | -12.9% | |
CCI | CROWN CASTLE INTL CORP | $10,525,000 | +8.4% | 130,700 | 0.0% | 1.47% | +11.3% | |
ACAD | ACADIA PHARMACEUTICALS INC | $10,478,000 | +9.6% | 423,200 | 0.0% | 1.46% | +12.5% | |
STKL | Buy | SUNOPTA INC | $10,255,000 | -12.7% | 849,600 | +1.8% | 1.43% | -10.4% |
IPHI | Buy | INPHI CORP | $9,839,000 | +5.7% | 684,200 | +7.9% | 1.37% | +8.5% |
PCYC | PHARMACYCLICS INC | $9,700,000 | +30.9% | 82,600 | 0.0% | 1.35% | +34.3% | |
TEX | TEREX CORP NEW | $9,642,000 | -22.7% | 303,500 | 0.0% | 1.35% | -20.6% | |
PTLA | PORTOLA PHARMACEUTICALS INC | $9,414,000 | -13.4% | 372,400 | 0.0% | 1.31% | -11.1% | |
CXP | COLUMBIA PPTY TR INC | $9,400,000 | -8.2% | 393,800 | 0.0% | 1.31% | -5.8% | |
ININ | Buy | INTERACTIVE INTELLIGENCE GRO | $9,288,000 | -10.2% | 222,200 | +20.6% | 1.30% | -7.8% |
ASML | ASML Holding NV | $9,269,000 | +5.9% | 93,800 | 0.0% | 1.29% | +8.7% | |
VMW | VMWARE INC | $9,178,000 | -3.1% | 97,800 | 0.0% | 1.28% | -0.5% | |
FPRX | FIVE PRIME THERAPEUTICS INC | $9,074,000 | -24.6% | 773,600 | 0.0% | 1.27% | -22.6% | |
VCYT | Buy | VERACYTE INC | $8,941,000 | +237.7% | 917,000 | +492.8% | 1.25% | +246.7% |
NVAX | NOVAVAX INC | $7,959,000 | -9.7% | 1,908,700 | 0.0% | 1.11% | -7.3% | |
CMRE | COSTAMARE INC | $7,910,000 | -5.8% | 360,200 | 0.0% | 1.10% | -3.3% | |
NRG | NRG ENERGY INC | $7,724,000 | -18.1% | 253,400 | 0.0% | 1.08% | -15.9% | |
STML | Buy | STEMLINE THERAPEUTICS INC | $7,224,000 | -12.0% | 579,800 | +3.6% | 1.01% | -9.7% |
LGND | LIGAND PHARMACEUTICALS INC | $7,034,000 | -24.6% | 149,700 | 0.0% | 0.98% | -22.6% | |
UFS | Sell | DOMTAR CORP | $6,977,000 | -37.0% | 198,600 | -23.2% | 0.97% | -35.4% |
OII | OCEANEERING INTL INC | $6,771,000 | -16.6% | 103,900 | 0.0% | 0.94% | -14.4% | |
PWR | QUANTA SVCS INC | $6,634,000 | +5.0% | 182,800 | 0.0% | 0.93% | +7.7% | |
BWA | BORGWARNER INC | $6,608,000 | -19.3% | 125,600 | 0.0% | 0.92% | -17.1% | |
AYR | AIRCASTLE LTD | $6,537,000 | -7.9% | 399,600 | 0.0% | 0.91% | -5.5% | |
TSLA | TESLA MTRS INC | $6,382,000 | +1.1% | 26,300 | 0.0% | 0.89% | +3.7% | |
FC | FRANKLIN COVEY CO | $6,183,000 | -2.7% | 315,600 | 0.0% | 0.86% | -0.1% | |
KAR | KAR AUCTION SVCS INC | $6,087,000 | -10.2% | 212,600 | 0.0% | 0.85% | -7.7% | |
TTPH | TETRAPHASE PHARMACEUTICALS I | $6,003,000 | +47.9% | 300,900 | 0.0% | 0.84% | +51.8% | |
P103PS | NPS PHARMACEUTICALS INC | $5,821,000 | -21.3% | 223,900 | 0.0% | 0.81% | -19.2% | |
SRPT | SAREPTA THERAPEUTICS INC | $5,467,000 | -29.2% | 259,100 | 0.0% | 0.76% | -27.3% | |
SCTY | SOLARCITY CORP | $5,304,000 | -15.6% | 89,000 | 0.0% | 0.74% | -13.2% | |
SGMO | SANGAMO BIOSCIENCES INC | $5,204,000 | -29.4% | 482,500 | 0.0% | 0.73% | -27.4% | |
AZPN | ASPEN TECHNOLOGY INC | $4,847,000 | -18.7% | 128,500 | 0.0% | 0.68% | -16.5% | |
NLNK | NEWLINK GENETICS CORP | $4,620,000 | -19.3% | 215,700 | 0.0% | 0.64% | -17.2% | |
CGNX | COGNEX CORP | $4,027,000 | +4.9% | 100,000 | 0.0% | 0.56% | +7.7% | |
MGNX | Buy | MACROGENICS INC | $3,992,000 | +11.5% | 191,000 | +15.9% | 0.56% | +14.4% |
AGTC | APPLIED GENETIC TECHNOL CORP | $3,824,000 | -19.4% | 205,500 | 0.0% | 0.53% | -17.3% | |
CLDX | CELLDEX THERAPEUTICS INC NEW | $3,742,000 | -20.6% | 288,700 | 0.0% | 0.52% | -18.6% | |
AKBA | AKEBIA THERAPEUTICS INC | $3,678,000 | -20.4% | 166,200 | 0.0% | 0.51% | -18.2% | |
RARE | ULTRAGENYX PHARMACEUTICAL IN | $2,977,000 | +26.1% | 52,600 | 0.0% | 0.42% | +29.6% | |
CERN | CERNER CORP | $2,317,000 | +15.5% | 38,900 | 0.0% | 0.32% | +18.3% | |
ATRC | ATRICURE INC | $2,242,000 | -19.9% | 152,300 | 0.0% | 0.31% | -17.8% | |
SUPN | Buy | SUPERNUS PHARMACEUTICALS INC | $2,233,000 | -15.3% | 257,000 | +6.8% | 0.31% | -12.8% |
NTUS | NATUS MEDICAL INC DEL | $2,213,000 | +17.3% | 75,000 | 0.0% | 0.31% | +20.7% | |
BMRN | BIOMARIN PHARMACEUTICAL INC | $2,179,000 | +16.0% | 30,200 | 0.0% | 0.30% | +18.8% | |
GWPH | GW PHARMACEUTICALS PLCads | $2,021,000 | -24.6% | 25,000 | 0.0% | 0.28% | -22.7% | |
RGEN | REPLIGEN CORP | $1,979,000 | -12.6% | 99,400 | 0.0% | 0.28% | -10.4% | |
CBST | CUBIST PHARMACEUTICALS INC | $1,924,000 | -5.0% | 29,000 | 0.0% | 0.27% | -2.2% | |
HPTX | HYPERION THERAPEUTICS INC | $1,924,000 | -3.4% | 76,300 | 0.0% | 0.27% | -0.7% | |
XLRN | ACCELERON PHARMA INC | $1,878,000 | -11.0% | 62,100 | 0.0% | 0.26% | -8.7% | |
SLXP | Sell | SALIX PHARMACEUTICALS INC | $1,844,000 | -31.4% | 11,800 | -45.9% | 0.26% | -29.8% |
ARWR | Buy | ARROWHEAD RESH CORP | $1,694,000 | +47.9% | 114,700 | +43.4% | 0.24% | +51.9% |
CEMP | CEMPRA INC | $1,686,000 | +2.2% | 153,800 | 0.0% | 0.24% | +4.9% | |
SAAS | INCONTACT INC | $1,681,000 | -5.3% | 193,300 | 0.0% | 0.24% | -2.9% | |
TGTX | Buy | TG THERAPEUTICS INC | $1,654,000 | +30.4% | 155,000 | +14.8% | 0.23% | +34.3% |
NBIX | NEUROCRINE BIOSCIENCES INC | $1,514,000 | +5.6% | 96,600 | 0.0% | 0.21% | +8.2% | |
ATHN | ATHENAHEALTH INC | $1,462,000 | +5.3% | 11,100 | 0.0% | 0.20% | +7.9% | |
SZYM | Sell | SOLAZYME INC | $1,417,000 | -68.7% | 190,000 | -50.6% | 0.20% | -67.9% |
MEIP | MEI PHARMA INC | $1,391,000 | +8.8% | 201,600 | 0.0% | 0.19% | +11.5% | |
BRKR | BRUKER CORP | $1,368,000 | -23.7% | 73,900 | 0.0% | 0.19% | -21.7% | |
PCRX | PACIRA PHARMACEUTICALS INC | $1,289,000 | +5.5% | 13,300 | 0.0% | 0.18% | +8.4% | |
SAGE | New | SAGE THERAPEUTICS INC | $1,266,000 | – | 40,200 | +100.0% | 0.18% | – |
CSII | CARDIOVASCULAR SYS INC DEL | $1,245,000 | -24.2% | 52,700 | 0.0% | 0.17% | -22.0% | |
INSM | INSMED INC | $1,156,000 | -34.7% | 88,600 | 0.0% | 0.16% | -33.2% | |
FEIC | FEI CO | $1,116,000 | -16.9% | 14,800 | 0.0% | 0.16% | -14.8% | |
TNDM | New | TANDEM DIABETES CARE INC | $1,074,000 | – | 80,000 | +100.0% | 0.15% | – |
KPTI | KARYOPHARM THERAPEUTICS INC | $1,048,000 | -25.0% | 30,000 | 0.0% | 0.15% | -23.2% | |
OMED | ONCOMED PHARMACEUTICALS INC | $1,000,000 | -18.7% | 52,800 | 0.0% | 0.14% | -16.2% | |
MDSO | MEDIDATA SOLUTIONS INC | $837,000 | +3.5% | 18,900 | 0.0% | 0.12% | +6.4% | |
DRNA | DICERNA PHARMACEUTICALS INC | $811,000 | -43.6% | 63,700 | 0.0% | 0.11% | -42.3% | |
ACRX | ACELRX PHARMACEUTICALS INC | $765,000 | -46.5% | 139,400 | 0.0% | 0.11% | -44.8% | |
XOMA | XOMA Corp | $746,000 | -8.2% | 177,200 | 0.0% | 0.10% | -6.3% | |
AAVL | New | AVALANCHE BIOTECHNOLOGIES IN | $684,000 | – | 20,000 | +100.0% | 0.10% | – |
AEGR | AEGERION PHARMACEUTICALS INC | $668,000 | +4.0% | 20,000 | 0.0% | 0.09% | +6.9% | |
SNSS | SUNESIS PHARMACEUTICALS INC | $655,000 | +9.3% | 91,800 | 0.0% | 0.09% | +12.3% | |
TFX | TELEFLEX INC | $609,000 | -0.5% | 5,800 | 0.0% | 0.08% | +2.4% | |
QURE | Buy | UNIQURE NV | $452,000 | +54.8% | 49,100 | +128.7% | 0.06% | +57.5% |
RPTP | RAPTOR PHARMACEUTICAL CORP | $387,000 | -17.1% | 40,400 | 0.0% | 0.05% | -15.6% | |
VSTM | VERASTEM INC | $178,000 | -5.8% | 20,900 | 0.0% | 0.02% | -3.8% | |
AMBI | Exit | AMBIT BIOSCIENCES CORP | $0 | – | -151,100 | -100.0% | -0.14% | – |
VSAR | Exit | VERSARTIS INC | $0 | – | -50,000 | -100.0% | -0.19% | – |
SDRL | Exit | SEADRILL LIMITED | $0 | – | -229,500 | -100.0% | -1.25% | – |
ROC | Exit | ROCKWOOD HLDGS INC | $0 | – | -170,400 | -100.0% | -1.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-12
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LOWES COS INC | 40 | Q3 2023 | 3.2% |
PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
VERACYTE INC | 38 | Q3 2023 | 1.5% |
LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR/A | 2024-02-20 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.